CAJ | 학술논문

背景:阿胶强骨口服液可有效治疗骨折,但其具体的药理学机制仍有待研究.在骨折愈合中,血管内皮生长因子和成纤维细胞生长因子2是促进血管内生以及骨的合成代谢的重要耦联因子.目的:观察阿胶强骨口服液对SD大鼠胫骨骨折愈合过程中骨痂中血管内皮生长因子和成纤维细胞生长因子2表达的影响,探讨阿胶强骨口服液治疗骨折的疗效机制.设计:完全随机对照实验.单位:华中科技大学同济医学院附属协和医院骨伤科研究室.材料:选用90只雌性3月龄SD大鼠,体质量(368±40)g,阿胶强骨口服液(主要成分为阿胶,新疆华世丹药业股份有限公司生产);阳性对照药接骨七厘片(主要成分为当归、乳香、没药、大黄、血竭、骨碎补、自然铜,珠海金沙(湖南)制药有限公司生产).方法:实验于2005-07/12在华中科技大学同济医学院中西结合骨代谢实验室(省级实验室)完成,采用三点弯曲方法造成大鼠右胫骨中段闭合性骨折后,采用完全随机法分为3组:阿胶强骨口服液组(n=30):按人鼠表面积比率换算等效计量法计算后,每只每次给予阿胶强骨口服液2 mL灌胃给药,2次/d;接骨七厘片组(n=30):用蒸馏水配制成225 g/L灌胃,2次/d;生理盐水组(n=30):给予同等容量,同等频率的生理盐水灌胃.分别在实验第4,7,14,21,28天采用免疫组织化学方法检测大鼠右胫骨骨痂区血管内皮生长因子和成纤维细胞生长因子2表达的变化,计算平均吸光度值及阳性细胞数(5个视野细胞).主要观察指标:各组大鼠右胫骨骨痂区血管内皮生长因子和成纤维细胞生长因子2表达(平均吸光度值及阳性细胞数).结果:纳入大鼠90只均进入结果分析.①血管内皮生长因子表达检测结果:实验开始后4,7,14 d,阿胶强骨口服液组大鼠及接骨七厘片组平均吸光度值均高于生理盐水组(P＜0.05～0.01),阳性细胞数变化幅度与平均吸光度值一致.②成纤维细胞生长因子2表达检测结果:实验开始后4,7 d,阿胶强骨口服液组及骨七厘片组成纤维细胞生长因子2平均吸光度值,均高于生理盐水组(P＜0.05～0.01),阳性细胞数变化幅度与平均吸光度值一致.结论:阿胶强骨口服液在骨愈合早中期可通过调节血管内皮生长因子和成纤维细胞生长因子2的表达,促进前成骨细胞和成软骨细胞的有丝分裂、血管内生以及骨的合成代谢达到促骨折愈合的作用. 揹景:阿膠彊骨口服液可有效治療骨摺,但其具體的藥理學機製仍有待研究.在骨摺愈閤中,血管內皮生長因子和成纖維細胞生長因子2是促進血管內生以及骨的閤成代謝的重要耦聯因子.目的:觀察阿膠彊骨口服液對SD大鼠脛骨骨摺愈閤過程中骨痂中血管內皮生長因子和成纖維細胞生長因子2錶達的影響,探討阿膠彊骨口服液治療骨摺的療效機製.設計:完全隨機對照實驗.單位:華中科技大學同濟醫學院附屬協和醫院骨傷科研究室.材料:選用90隻雌性3月齡SD大鼠,體質量(368±40)g,阿膠彊骨口服液(主要成分為阿膠,新疆華世丹藥業股份有限公司生產);暘性對照藥接骨七釐片(主要成分為噹歸、乳香、沒藥、大黃、血竭、骨碎補、自然銅,珠海金沙(湖南)製藥有限公司生產).方法:實驗于2005-07/12在華中科技大學同濟醫學院中西結閤骨代謝實驗室(省級實驗室)完成,採用三點彎麯方法造成大鼠右脛骨中段閉閤性骨摺後,採用完全隨機法分為3組:阿膠彊骨口服液組(n=30):按人鼠錶麵積比率換算等效計量法計算後,每隻每次給予阿膠彊骨口服液2 mL灌胃給藥,2次/d;接骨七釐片組(n=30):用蒸餾水配製成225 g/L灌胃,2次/d;生理鹽水組(n=30):給予同等容量,同等頻率的生理鹽水灌胃.分彆在實驗第4,7,14,21,28天採用免疫組織化學方法檢測大鼠右脛骨骨痂區血管內皮生長因子和成纖維細胞生長因子2錶達的變化,計算平均吸光度值及暘性細胞數(5箇視野細胞).主要觀察指標:各組大鼠右脛骨骨痂區血管內皮生長因子和成纖維細胞生長因子2錶達(平均吸光度值及暘性細胞數).結果:納入大鼠90隻均進入結果分析.①血管內皮生長因子錶達檢測結果:實驗開始後4,7,14 d,阿膠彊骨口服液組大鼠及接骨七釐片組平均吸光度值均高于生理鹽水組(P＜0.05～0.01),暘性細胞數變化幅度與平均吸光度值一緻.②成纖維細胞生長因子2錶達檢測結果:實驗開始後4,7 d,阿膠彊骨口服液組及骨七釐片組成纖維細胞生長因子2平均吸光度值,均高于生理鹽水組(P＜0.05～0.01),暘性細胞數變化幅度與平均吸光度值一緻.結論:阿膠彊骨口服液在骨愈閤早中期可通過調節血管內皮生長因子和成纖維細胞生長因子2的錶達,促進前成骨細胞和成軟骨細胞的有絲分裂、血管內生以及骨的閤成代謝達到促骨摺愈閤的作用.
배경:아효강골구복액가유효치료골절,단기구체적약이학궤제잉유대연구.재골절유합중,혈관내피생장인자화성섬유세포생장인자2시촉진혈관내생이급골적합성대사적중요우련인자.목적:관찰아효강골구복액대SD대서경골골절유합과정중골가중혈관내피생장인자화성섬유세포생장인자2표체적영향,탐토아효강골구복액치료골절적료효궤제.설계:완전수궤대조실험.단위:화중과기대학동제의학원부속협화의원골상과연구실.재료:선용90지자성3월령SD대서,체질량(368±40)g,아효강골구복액(주요성분위아효,신강화세단약업고빈유한공사생산);양성대조약접골칠전편(주요성분위당귀、유향、몰약、대황、혈갈、골쇄보、자연동,주해금사(호남)제약유한공사생산).방법:실험우2005-07/12재화중과기대학동제의학원중서결합골대사실험실(성급실험실)완성,채용삼점만곡방법조성대서우경골중단폐합성골절후,채용완전수궤법분위3조:아효강골구복액조(n=30):안인서표면적비솔환산등효계량법계산후,매지매차급여아효강골구복액2 mL관위급약,2차/d;접골칠전편조(n=30):용증류수배제성225 g/L관위,2차/d;생리염수조(n=30):급여동등용량,동등빈솔적생리염수관위.분별재실험제4,7,14,21,28천채용면역조직화학방법검측대서우경골골가구혈관내피생장인자화성섬유세포생장인자2표체적변화,계산평균흡광도치급양성세포수(5개시야세포).주요관찰지표:각조대서우경골골가구혈관내피생장인자화성섬유세포생장인자2표체(평균흡광도치급양성세포수).결과:납입대서90지균진입결과분석.①혈관내피생장인자표체검측결과:실험개시후4,7,14 d,아효강골구복액조대서급접골칠전편조평균흡광도치균고우생리염수조(P＜0.05～0.01),양성세포수변화폭도여평균흡광도치일치.②성섬유세포생장인자2표체검측결과:실험개시후4,7 d,아효강골구복액조급골칠전편조성섬유세포생장인자2평균흡광도치,균고우생리염수조(P＜0.05～0.01),양성세포수변화폭도여평균흡광도치일치.결론:아효강골구복액재골유합조중기가통과조절혈관내피생장인자화성섬유세포생장인자2적표체,촉진전성골세포화성연골세포적유사분렬、혈관내생이급골적합성대사체도촉골절유합적작용.
BACKGROUND:Donkey-hide glue reinforcing bone oral solution (DGRBOS) is effective on preventing and treating fracture, but the mechanism of harmacology is still not clear. Vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF-2) are important cytokines, which can promote blood vessel growth and osseous anabolism during fracture healing.OBJECTIVE: To investigate the effects of DGRBOS on expression of VEGF and FGF-2 in the process of fracture healing of SD rats' fracture of tibia in bony callus, and explore the mechanism of DGRBOS in the treatment of fracture.DESIGN: A completely randomized controlled study.SETTING: Department of Traumatic Orthopedics, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology.MATERIALS: Ninety female Sprague-Dawley (SD) rats, with a mean weight of (368±40) g, aged about 3 months, wereprovided by Center of Animal Experiment, Tongji Medical College, Huazhong University of Science and Technology.Experimental drug: DGRBOS was donated by Xinjiang Huashidan Pharmaceutical Co., Ltd. The qili linking bone pill,positive control drug, was purchased from Hunan Pharmaceutical Co., Ltd.METHODS: This experiment was carried out in the Laboratory for Bone Metabolism of Integration of Chinese and Western Medicine (Laboratory of Provincial Level), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from June to November 2005. Transverse midshaft fractures were produced on the right tibia in these rats using three-point bending technique, and 90 rats were randomly divided into three experimental groups:the DGRBOS group (n =30): according to medicine conversional method between human being and animal, 2 mL DGRBOS was fed to every mouse by intragastric administration at 2 vices/day; the qili linking bone pill group (positive control group, n =30): the pills dissolved in distilled water at 225 g/L, and consequently were administered intragastrically into mice at 2 mL/vice and 2 vices/day; normal saline group (negative control group, n =30): normal saline was administered intragastrically into mice at the coordinative capacity and same frequences. Selecting 4, 7, 14,21 and 28 days during the experiment, the immunohistochemistry method was adopted to detect the change of expression of VEGF and FGF-2 through computing value of mean optical degree (MOD) and number of the positive cells.